Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, mitotane (Lysodren®) cannot be endorsed for use within NHS Wales for the treatment of symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. |
||
|
||
Medicine details |
||
| Medicine name | mitotane (Lysodren®) | |
| Formulation | 500 mg tablet | |
| Reference number | 1442 | |
| Indication | For use within NHS Wales for the treatment of symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. |
|
| Company | HRA Pharma UK & Ireland Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 19/06/2012 | |
| Date of issue | 19/06/2012 | |